SynthesisFrontiers in immunology2018
The Use of Human Mesenchymal Stem Cells as Therapeutic Agents for the
Synthesis in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 3 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Hematopoietic stem cell translation for relapse of psoriasis. Systematic review.Archives of dermatological research · 2025Pooled it
- Effect of mesenchymal stromal cells-derived extracellular vesicles as a treatment to heal diabetic wounds: A meta-analysis.International wound journal · 2023Pooled it
- MSC-Derived Extracellular Vesicles to Heal Diabetic Wounds: a Systematic Review and Meta-Analysis of Preclinical Animal Studies.Stem cell reviews and reports · 2022Pooled it
- Developmental Toxicity of Chlorinated Polyfluorinated Ether Sulfonate (F-53B), a Perfluorooctane Sulfonate (PFOS) Alternative, in Embryos and Larvae of Blotched Snakehead (Antioxidants (Basel, Switzerland) · 2026Article
- Mesenchymal Stem Cells Ameliorate Acute-on-Chronic Liver Failure Associated With Expansion of Immunoregulatory Hepatic NKp46Journal of immunology research · 2026Article
- Mesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of Myasthenia Gravis.Stem cell research & therapy · 2025Article
- Unveiling new therapeutic horizons in rheumatoid arthritis: an In-depth exploration of circular RNAs derived from plasma exosomes.Journal of orthopaedic surgery and research · 2025Article
- Comparison of administration methods in adipose tissue-derived stem cell therapy in rats with colitis: An experimental study.Northern clinics of Istanbul · 2025Article
- New insights into mesenchymal stem cells in inflammatory subtypes of asthma.Frontiers in immunology · 2025Review
- LOCAL INJECTION OF HUMAN DENTAL PULP STEM CELLS FOR TREATMENT OF JUVENILE AVASCULAR NECROSIS OF THE FEMORAL HEAD: PRELIMINARY RESULTS IN IMMATURE PIGS.Acta ortopedica brasileira · 2025Article
- Enhanced Therapeutic Effects of Human Mesenchymal stem Cells Transduced with Secreted Klotho in a Murine Experimental Autoimmune Encephalomyelitis Model.Molecular neurobiology · 2024Article
- The role of mitochondrial transfer in the suppression of CD8Stem cell research & therapy · 2024Article
- Potential use of stem cell therapies for treating osteoarthritis and rheumatoid arthritis.Annals of translational medicine · 2024Review
- PL-hMSC and CH-hMSC derived soluble factors inhibit proliferation but improve hGBM cell migration by activating TGF-β and inhibiting Wnt signaling.Bioscience reports · 2024Article
- Inflammation-inducible promoters to overexpress immune inhibitory factors by MSCs.Stem cell research & therapy · 2023Article
- Myasthenia Gravis: Novel Findings and Perspectives on Traditional to Regenerative Therapeutic Interventions.Aging and disease · 2023Article
- Current developments and therapeutic potentials of exosomes from induced pluripotent stem cells-derived mesenchymal stem cells.Journal of the Chinese Medical Association : JCMA · 2023Review
- Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the "First in Cystic Fibrosis" Phase I Clinical Trial (CEASE-CF).Pharmaceuticals (Basel, Switzerland) · 2023Article
- Transfer of mesenchymal stem cell mitochondria to CD4Stem cell research & therapy · 2023Article
- Rationale for combined therapies in severe-to-critical COVID-19 patients.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.